First H Pylori Vaccine Receives Approval

China's State Food and Drug Administration (SFDA) has approved a third domestically-developed pharmaceutical agent in a matter of months. BMI believes these developments endorse the country's small but rapidly expanding research and development sector. However, the lack of clinical trial data on the medicines in the public domain is a concern.

To read the full article, please choose one of the following options: